REPRO-MED Systems earnings date
Want to see KRMD full AI Analyst Report?
REPRO-MED Systems (KRMD) Q3 2026 Earnings Report
KRMD Q3 2026 EPS Results
- Actual EPS
- $0.00
- Consensus EPS
- -$0.02
- Beat/Miss
- Beat by +$0.02
- One Year Ago EPS
- -$0.02
KRMD Q3 2026 Revenue Results
- Actual Revenue
- $11.57M
- Expected Revenue
- $11.33M
- Beat/Miss
- Beat by +$240.56K
- YoY Revenue Growth
- +11.19%
Earnings Announcement Details
- Quarter
- Q3 2026
- Date
- 11/10/2026
- Time
- After Close
- Conference Call
- Tuesday, November 10, 2026
REPRO-MED Systems's next earnings date is estimated for March 17, 2027, based on past reporting schedules.
Q3 2026 Earnings Call Audio
Q3 2026 Earnings Slide Deck
Q3 2026 Earnings Call Summary
The call was strongly positive overall. KORU reported double-digit revenue growth, a 500 basis point gross-margin expansion, a second consecutive quarter of positive net income and adjusted EBITDA, significant year-to-date operating leverage, new distribution partnerships, pipeline progress and raised full-year guidance. The principal challenges were slower-than-desired third-quarter top-line growth, a reported international revenue decline caused by distributor timing and market-launch dynamics, lower variable pharma-services revenue, quarterly cash usage and ongoing regulatory and pipeline timing uncertainty.
Management guided to full-year 2026 revenue of $48 million to $48.5 million, representing 17% to 18% growth for the year, versus the prior range of $47.5 million to $48.5 million; gross margin guidance is 63% to 64%, versus the prior 62% to 64%; and the company expects positive adjusted EBITDA for the full year. Management expects high teens growth in Q4, core revenue growth of between 17% and 19% to finish the year, full-year cash usage coming in under $900,000, anticipated positive cash flow of at least $600,000 in Q4 itself, and a year-end cash balance above $8 million, versus the prior $7.5 million target. Long-term targets remain unchanged at $100 million in revenue, gross margins above 65% and EBITDA margins of 20% or greater; management also said deferoxamine is anticipated to be a contributor in 2027 and beyond, secondary immunodeficiency pivotal trial endpoints are expected toward the end of 2027, and further oncology details are planned in the first half of 2027.
- Revenue Growth and Margin ExpansionThird-quarter revenue was $11.6 million, up 11% year-over-year, while gross margin expanded to 65.2% from 60.2% in the prior-year period, a 500 basis point improvement. The company delivered its second consecutive quarter of positive net income and adjusted EBITDA.
- Strong Domestic Core PerformanceDomestic core revenue was $8.1 million. Reported revenue grew 32% year-over-year, while normalized growth was 10%, driven by higher pump and consumable volumes, new patient starts, market share gains and a strong underlying SCIg market.
- Healthy Normalized International GrowthNormalized international core revenue increased 23% year-over-year, driven by new patient starts within existing markets. Management said the underlying international trajectory remains healthy and expects fourth-quarter international performance to be strong.
- RYSTIGGO Specialty Pharmacy Channel LaunchThree U.S. specialty pharmacies began dispensing KORU products to support home administration of RYSTIGGO; two use the complete KORU system and one uses only the needle set. Management expects RYSTIGGO to drive growth as new patient starts increase and estimates the total RYSTIGGO market potential at around 100,000 infusions over the next 3 to 5 years.
- New European Distribution PartnershipKORU signed a sales and distribution agreement with a partner in one of Europe's largest markets, received its first order, and expects benefits to begin in the fourth quarter. The partner combines wholesaler, home care provider and pharmacy capabilities and will use the KORU Freedom Infusion System across multiple countries.
- Expansion into AfricaKORU signed a sales and distribution agreement with a new partner in Africa and shipped the initial order during the quarter, broadening the company's global footprint and bringing subcutaneous infusion therapy to a new patient population.
- Large Recurring Patient Base and Growing SCIg MarketApproximately 60,000 chronic recurring immunoglobulin patients rely on the Freedom system every day. Management said the Ig market continues to grow in the high single digits annually, while the SCIg market is growing approximately 8% to 10% year-over-year and 1.8% to 2% quarter-over-quarter.
- Facilitated Subcutaneous Therapy ProgressA pivotal Phase II/III trial of an investigational facilitated subcutaneous immunoglobulin 20% therapy met its primary endpoint. Compared with HYQVIA, the therapy delivered the same IgG dose in half the volume, shortened infusion times by more than 40% for a single infusion site and maintained up to once-monthly dosing.
- Enzyme Replacement Therapy Phase III AdvancementPatients are being dosed with the KORU Freedom Infusion System in a pharmaceutical partner's Phase III trial for an investigational enzyme replacement therapy. The estimated patient population is approximately 5,000 patients.
- Nephrology Collaboration ExpansionA pharmaceutical partner approaching a Phase III trial for a nephrology asset executed a follow-on statement of work to support international clinical trials. The drug has an estimated patient population of approximately 10,000 patients.
- Deferoxamine Regulatory ProgressKORU's 510(k) application for deferoxamine remains under FDA review. The company is pursuing the label independently of a pharmaceutical partnership, anticipates deferoxamine will be a contributor in 2027 and beyond, and said it believes clearance could come in the near term.
- Secondary Immunodeficiency and Oncology OpportunitiesKORU continues to pursue secondary immunodeficiency opportunities and expects pivotal trial endpoints toward the end of 2027, with many trials using SCIg drugs already on the KORU label. Management also reiterated strong conviction in oncology as a long-term growth inflection opportunity and plans to provide further details in the first half of 2027.
- Freedom360 Development On TrackThe company is completing the final touches on its regulatory submission for the next-generation Freedom360 pump, which remains firmly on track for filing by the end of the year. Management said the product is particularly suited to patients whose doses require multiple prefilled syringes.
- Connected Health Technology ProgressFollowing the acquisition of a connected monitoring technology asset in the second quarter, KORU has developed functional prototypes and is using them in discussions with pharmaceutical and specialty pharmacy companies. Management said initial partner feedback has been enthusiastic and very positive.
- Year-to-Date Operating LeverageYear-to-date revenue was $35.4 million versus $30.2 million last year, up 17%. Gross margin increased to 64% from 62.1%, operating expenses as a percentage of sales improved from 70.2% to 64%, net loss narrowed from $2.2 million to $300,000, an 84% improvement, and adjusted EBITDA increased from $100,000 to $2.2 million, roughly an 18x year-over-year improvement.
- Improving Manufacturing EconomicsGross-margin improvement was supported by lower manufacturing costs from production-throughput efficiencies, lower tariffs, higher average selling prices from favorable geographic mix and an extended contract manufacturer supply agreement that secures pricing and volume efficiencies.
- Positive Fourth-Quarter Cash Flow OutlookKORU ended the quarter with $7.4 million in cash, was net-income positive by $200,000 and retained access to an undrawn $10 million debt facility. Management expects positive cash flow in the fourth quarter, including at least $600,000 of positive fourth-quarter cash flow.
- Raised Full-Year GuidanceThe company raised the bottom end of full-year revenue guidance to $48 million-$48.5 million, representing 17% to 18% growth, from the prior range of $47.5 million-$48.5 million. It also raised the gross-margin range to 63%-64% from 62%-64%, expects positive adjusted EBITDA for the full year and raised its year-end cash balance target to above $8 million from $7.5 million.
- Long-Term Financial Targets MaintainedKORU maintained its long-term targets of $100 million in revenue, gross margins above 65% and EBITDA margins of 20% or greater.
KRMD Earnings History
| Report Date | Fiscal Quarter | Forecast / EPS | Last Year's EPS | EPS YoY Change | Press Release |
|---|---|---|---|---|---|
| Mar 17, 2027 | 2026 (Q4) | -0.00- | -0.01 | ― | ― |
| Nov 10, 2026 | 2026 (Q3) | -0.020.00 | -0.02 | 100.00% (+0.02) | |
| Aug 05, 2026 | 2026 (Q2) | -0.020.01 | 0.01 | 0.00% (+0.00) | |
| May 06, 2026 | 2026 (Q1) | -0.02-0.02 | 0 | ― | |
| Mar 12, 2026 | 2025 (Q4) | -0.02-0.01 | -0.03 | 66.67% (+0.02) | |
| Nov 12, 2025 | 2025 (Q3) | -0.02-0.02 | -0.03 | 33.33% (+0.01) | |
| Aug 06, 2025 | 2025 (Q2) | -0.020.01 | -0.01 | 200.00% (+0.02) | |
| May 07, 2025 | 2025 (Q1) | -0.030.00 | -0.04 | 100.00% (+0.04) | |
| Mar 12, 2025 | 2024 (Q4) | -0.03-0.03 | -0.02 | -50.00% (-0.01) | |
| Nov 13, 2024 | 2024 (Q3) | -0.04-0.03 | -0.03 | 0.00% (+0.00) |
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.


